{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:06:11Z","timestamp":1794081971912,"version":"4.8.0"},"reference-count":42,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Tenalisib, a selective phosphoinositide-3-kinase \u03b4\/\u03b3, and salt-inducible-kinase-3 inhibitor has shown efficacy and was well-tolerated in patients with T-cell lymphoma (TCL). In vitro studies suggest a synergistic anti-tumor potential for the combination of tenalisib with the histone-deacetylase inhibitor, romidepsin. This multicenter, open-label, phase I\/II study was designed to characterize the safety, efficacy and pharmacokinetics of oral tenalisib twice-daily and intravenous romidepsin administered on days 1, 8 and 15 in 28-day cycles in adults with relapsed\/refractory TCL. Phase I\/dose escalation determined the maximum tolerated dose (MTD)\/optimal doses of tenalisib and romidepsin. The phase II\/dose expansion assessed the safety and anti-tumor activity of the combination at MTD\/optimal dose. Overall, 33 patients were enrolled. In dose escalation, no dose-limiting toxicity was identified. Hence, the recommended doses for dose expansion were tenalisib 800 mg twice daily orally, and romidepsin 14 mg\/m2 intravenous. Overall treatment-emergent adverse events of any grade reported in &gt;15% of patients were nausea, thrombocytopenia, increased aspartate aminotransferase, increased alanine aminotransferase, decreased appetite, neutropenia, vomiting, fatigue, anemia, dysgeusia, weight loss, diarrhea, and hypokalemia. Twenty-three patients (69.7%) had related grade \u22653 treatment-emergent adverse events. The overall objective response rate in evaluable patients was 63.0% (peripheral TCL: 75% and cutaneous TCL: 53.3%), with a complete response and partial response of 25.9% and 37.0% respectively. The median duration of response was 5.03 months. Co-administration of tenalisib and romidepsin did not significantly alter the pharmacokinetics of romidepsin. Overall, tenalisib and romidepsin combination demonstrated a favorable safety and efficacy profile supporting its further development for relapsed\/refractory TCL (clinicaltrials gov. Identifier: NCT03770000).<\/jats:p>","DOI":"10.3324\/haematol.2022.281875","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T04:00:30Z","timestamp":1689220830000},"page":"209-219","source":"Crossref","is-referenced-by-count":18,"title":["Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study"],"prefix":"10.3324","volume":"109","author":[{"given":"Swaminathan P.","family":"Iyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Auris","family":"Huen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Lechowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Alderuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Champion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Mohrbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasi V.","family":"Routhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajak","family":"Barde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit M.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley M.","family":"Haverkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"56366","doi-asserted-by":"crossref","unstructured":"Rodd AL, Ververis K, Karagiannis TC. Current and emerging therapeutics for cutaneous T-cell lymphoma: histone deacetylase inhibitors. Lymphoma. 2012; 2012:1-10.","DOI":"10.1155\/2012\/290685"},{"key":"56367","doi-asserted-by":"crossref","unstructured":"Lauenborg B, Christensen L, Ralfkiaer U. Malignant T cells express lymphotoxin \u03b1 and drive endothelial activation in cutaneous T cell lymphoma. Oncotarget. 2015; 6(17):15235-15249.","DOI":"10.18632\/oncotarget.3837"},{"key":"56368","doi-asserted-by":"crossref","unstructured":"Pellegrini C, Dodero A, Chiappella A. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed\/refractory peripheral T-cell lymphoma patients. J Hematol Oncol. 2016; 9:38.","DOI":"10.1186\/s13045-016-0266-1"},{"key":"56369","doi-asserted-by":"crossref","unstructured":"Foss F, Pro B, Miles Prince H. Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer Med. 2017; 6(1):36-44.","DOI":"10.1002\/cam4.939"},{"key":"56370","unstructured":"Duvic M, Martin AG, Kim Y. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001; 137(5):581-593."},{"key":"56371","doi-asserted-by":"crossref","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007; 12(10):1247-1252.","DOI":"10.1634\/theoncologist.12-10-1247"},{"key":"56372","doi-asserted-by":"crossref","unstructured":"O'Connor OA, Horwitz S, Masszi T. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015; 33(23):2492-2499.","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"56373","doi-asserted-by":"crossref","unstructured":"O'Connor OA, Pro B, Pinter-Brown L. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29(9):1182-1189.","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"56374","doi-asserted-by":"crossref","unstructured":"Ogura M, Ishida T, Hatake K. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014; 32(11):1157-1163.","DOI":"10.1200\/JCO.2013.52.0924"},{"key":"56375","doi-asserted-by":"crossref","unstructured":"Flinn IW, O'Brien S, Kahl B. Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies. Blood. 2018; 131(8):877-887.","DOI":"10.1182\/blood-2017-05-786566"},{"key":"56376","doi-asserted-by":"crossref","unstructured":"Duvic M, Tetzlaff MT, Gangar P, Clos AL, Sui D, Talpur R. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015; 33(32):3759-3765.","DOI":"10.1200\/JCO.2014.60.3787"},{"key":"56377","doi-asserted-by":"crossref","unstructured":"Prince HM, Kim YH, Horwitz SM. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017; 390(10094):555-566.","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"56378","doi-asserted-by":"crossref","unstructured":"Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol. 2018; 15(5):273-291.","DOI":"10.1038\/nrclinonc.2018.28"},{"key":"56379","doi-asserted-by":"crossref","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019; 18(1):26.","DOI":"10.1186\/s12943-019-0954-x"},{"key":"56380","doi-asserted-by":"crossref","unstructured":"Katsuya H, Cook LBM, Rowan AG, Satou Y, Taylor GP, Bangham CRM. Phosphatidylinositol 3-kinase-\u03b4 (PI3K-\u03b4) is a potential therapeutic target in adult T-cell leukemia-lymphoma. Biomark Res. 2018; 6:24.","DOI":"10.1186\/s40364-018-0138-7"},{"key":"56381","doi-asserted-by":"crossref","unstructured":"Flinn IW, Kahl BS, Leonard JP. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014; 123(22):3406-3413.","DOI":"10.1182\/blood-2013-11-538546"},{"key":"56382","doi-asserted-by":"crossref","unstructured":"Flinn IW, O'Brien S, Kahl B. Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies. Blood. 2018; 131(8):877-887.","DOI":"10.1182\/blood-2017-05-786566"},{"key":"56383","unstructured":"Dreyling M, Panayiotidis P, Egyed M. Efficacy of copanlisib monotherapy in patients with relapsed or refractory marginal zone lymphoma: subset analysis from the CHRONOS-1 trial. Blood. 2017; 130(Suppl 1):S4053."},{"key":"56384","doi-asserted-by":"crossref","unstructured":"Carlo-Stella C, Delarue R, Scarfo L. A First-in-human study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor, in patients with relapsed\/refractory hematologic malignancies: results from the European Study. Clin Lymphoma Myeloma Leuk. 2020; 20(2):78-86.","DOI":"10.1016\/j.clml.2019.10.013"},{"key":"56385","doi-asserted-by":"crossref","unstructured":"Grosicki S, Iosava G, Zodelava M. An open label, phase 2 study to assess the efficacy and safety of tenalisib (RP6530), a PI3K \u03b4\/\u03b3 and SIK3 inhibitor, in patients with relapsed\/refractory chronic lymphocytic leukemia (CLL). Blood. 2020; 136(Suppl 1):S25.","DOI":"10.1182\/blood-2020-136031"},{"key":"56386","doi-asserted-by":"crossref","unstructured":"Huen A, Haverkos BM, Zain J. Phase I\/Ib study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with relapsed\/refractory T-cell lymphoma. Cancers (Basel). 2020; 12(8):2293.","DOI":"10.3390\/cancers12082293"},{"key":"56387","doi-asserted-by":"crossref","unstructured":"Chen F, Chen L, Qin Q, Sun X. Salt-inducible kinase 2: an oncogenic signal transmitter and potential target for cancer therapy. Front Oncol. 2019; 9:18.","DOI":"10.3389\/fonc.2019.00018"},{"key":"56388","doi-asserted-by":"crossref","unstructured":"Bon H, Wadhwa K, Schreiner A. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Mol Cancer Res. 2015; 13(4):620-635.","DOI":"10.1158\/1541-7786.MCR-13-0182-T"},{"key":"56389","doi-asserted-by":"crossref","unstructured":"Sorrentino A, Menevse AN, Michels T. Salt-inducible kinase 3 protects tumor cells from cytotoxic T-cell attack by promoting TNF-induced NF-\u03baB activation. J Immunother Cancer. 2022; 10(5):e004258.","DOI":"10.1136\/jitc-2021-004258"},{"key":"56390","doi-asserted-by":"crossref","unstructured":"Charoenfuprasert S, Yang YY, Lee YC. Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer. Oncogene. 2011; 30(33):3570-3584.","DOI":"10.1038\/onc.2011.77"},{"key":"56391","doi-asserted-by":"crossref","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017; 18(7):1414.","DOI":"10.3390\/ijms18071414"},{"key":"56392","doi-asserted-by":"crossref","unstructured":"VanderMolen K, McCulloch W, Pearce C. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J Antibiot. 2011; 64:525-531.","DOI":"10.1038\/ja.2011.35"},{"key":"56393","doi-asserted-by":"crossref","unstructured":"Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019; 16(8):494-507.","DOI":"10.1038\/s41571-019-0190-8"},{"key":"56394","doi-asserted-by":"crossref","unstructured":"Hontecillas-Prieto L, Flores-Campos R, Silver A, de \u00c1lava E, Hajji N, Garc\u00eda-Dom\u00ednguez DJ. Synergistic enhancement of cancer therapy using HDAC inhibitors: opportunity for clinical trials. Front Genet. 2020; 11:578011.","DOI":"10.3389\/fgene.2020.578011"},{"key":"56395","doi-asserted-by":"crossref","unstructured":"Ranganna K, Selvam C, Shivachar A, Yousefipour Z. Histone deacetylase inhibitors as multitarget-directed Epi-drugs in blocking PI3K oncogenic signaling: a polypharmacology approach. Int J Mol Sci. 2020; 21(21):8198.","DOI":"10.3390\/ijms21218198"},{"key":"56396","doi-asserted-by":"crossref","unstructured":"Moskowitz AJ, Koch R, Mehta-Shah N. In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, in combination with romidepsin or bortezomib in relapsed\/refractory T-cell lymphoma. Blood. 2017; 130(Suppl 1):S819.","DOI":"10.1182\/blood.V130.Suppl_1.819.819"},{"key":"56397","doi-asserted-by":"crossref","unstructured":"Horwitz SM, Moskowitz AJ, Jacobsen ED. The Combination of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts. Blood. 2018; 132(Suppl 1):S683.","DOI":"10.1182\/blood-2018-99-115241"},{"key":"56398","doi-asserted-by":"crossref","unstructured":"Yan Z, Zhang K, Ji M, Xu H, Chen X. A Dual PI3K\/HDAC inhibitor downregulates oncogenic pathways in hematologic tumors in vitro and in vivo. Front Pharmacol. 2021; 12:741697.","DOI":"10.3389\/fphar.2021.741697"},{"key":"56399","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF. Recommendations for Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano Classification. J Clin Oncol. 2014; 32(27):3059-3067.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"56400","doi-asserted-by":"crossref","unstructured":"Olsen EA, Whittaker S, Kim YH, International Society for Cutaneous Lymphomas; United States Cutaneous Lymphoma Consortium; Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011; 29(18):2598-2607.","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"56401","doi-asserted-by":"crossref","unstructured":"Duvic M, Bates SE, Piekarz R. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018; 59(4):880-887.","DOI":"10.1080\/10428194.2017.1361022"},{"key":"56402","doi-asserted-by":"crossref","unstructured":"Amengual JE, Lichtenstein R, Lue J. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018; 131(4):397-407.","DOI":"10.1182\/blood-2017-09-806737"},{"key":"56403","doi-asserted-by":"crossref","unstructured":"O'Connor OA, Falchi L, Lue JK. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019; 134(17):1395-1405.","DOI":"10.1182\/blood.2019001285"},{"key":"56404","doi-asserted-by":"crossref","unstructured":"Coiffier B, Pro B, Prince HM. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30(6):631-636.","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"56405","doi-asserted-by":"crossref","unstructured":"Iyer SP, Foss FF. Romidepsin for the treatment of peripheral T-cell lymphoma. Oncologist. 2015; 20(9):1084-1091.","DOI":"10.1634\/theoncologist.2015-0043"},{"key":"56406","unstructured":"ISTODAX\u00ae (romidepsin) [prescribing information]. ISTODAX (romidepsin) Label. 2023."},{"key":"56407","doi-asserted-by":"crossref","unstructured":"Bachy E, Camus V, Thieblemont C. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (Conducted by LYSA). J Clin Oncol. 2022; 40(3):242-251.","DOI":"10.1200\/JCO.21.01815"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281875\/75816","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281875\/76443","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11144\/75816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:25Z","timestamp":1794045865000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,13]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281875","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,13]]}}}